Loading
A phase 2 trial of Dostarlimab in colorectal cancer, run by GlaxoSmithKline, active and no longer recruiting.
A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China is a phase 2 interventional study registered as NCT06640049 by GlaxoSmithKline, with 23 participants enrolled, started 2024-10-17 and due to reach its primary completion in 2027-10-24. Interventions recorded: Dostarlimab.
Shares Dostarlimab, GSK, Colorectal cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares GSK, Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer and the tag pipeline.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Rectal cancer, Colorectal cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.